

HARMONY

Healthcare Alliance for Resourceful Medicines
Offensive against Neoplasms in Hematology

4th General Assembly

26 & 27 september 2019
Florence, Italy

HANDOUT



We are HARMONY!

PARTNERS: Abbvie, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) | Amgen | Assistance Publique- Hopitaux de Paris (AP-HP) | Barts Health NHS Trust | Bayer AG | BFARM Bundesinstitut für Arzneimittel und Medizinprodukte | Celgene | Charité – Universitätsmedizin Berlin | EAPM (European Alliance for Personalised Medicine) | ELN Foundation | EORTC (European Organisation for Research and Treatment of Cancer) | Erasmus MC Cancer Institute Rotterdam | ERIC European Research Initiative on CLL | European Group for Blood and Marrow Transplantation | European Hematology Association (EHA) | FisMonlus Fondazione Italiana Sindromi Mielodisplastiche | Flanders Institute of Biotechnology (VIB) | Genome Research Limited (GRL-SANGER) | German Society of Pediatric Onco-hema (GPOH) | GMV Soluciones Globales Internet | Goethe University Frankfurt (GUF) | GRAALL Group for Research on Adult ALL | Groupe Francophone des Myelodysplasies (GFM) | Heinrich-Heine-Universitaet-Dusseldorf | Hospital Universitario La Fe de la Comunidad Valenciana (HULAFE) | IBSAL | IJC Josep Carreras Leukaemia Research Institute | Janssen | LeukaNET Patient Advocacy Group | LMU Ludwig Maximilians Universitaet München | Lymphoma Scientific Association (LYSA) | Masarykova Univerzita | MediSapiens | Medizinische Universitaet Wien | Menarini Ricerche | Munich Leukemia Laboratory (MLL) | NICE (National Institute for Health and Care Excellence) | Novartis | OPBG & AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) | SYNAPSE Research Management Partners | Takeda | UNAV Universidad de Navarra | UNIBO Alma Mater Studiorum - Università di Bologna | UNITO Università degli studi di Torino | Universitaet Ulm | University Hospital Vall d'Hebron | University of Cambridge | University of Helsinki | University of Newcastle upon Tyne | University of Rome Tor Vergata | University of York | VU University Medical Center.

PATIENT CLUSTER: Acute Leukemia Advocates Network (ALAN) | Childhood Cancer International (CCI) | CLL Advocates Network | LeukaNET Patient Advocacy Group | Lymphoma Coalition | MDS Foundation | Myeloma Patients Europe.

ASSOCIATED MEMBERS: Aghia Sophia Hospital | ALFA Group | Azienda Ospedaliero Universitaria di Ferrara | Carol Davila University of Medicine and Pharmacy | Centre Hospitalier Universitaire de Nice | CZECH Leukemia Study Group | European Myeloma Network | FICUS | Fondazione GIMEMA | Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico | GELTAMO (Grupo Español de linfomas y trasplantes de médula ósea) | GESMD (Grupo Español de Síndromes Mielodisplásicos) | Hospital 12 de Octubre | Hospital del Mar | HOVON (Haemato Oncology Foundation for Adults in the Netherlands) | INAB/CERTH (Institute of Applied Biosciences at the Center for Research and Technology Hellas) | Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST IRCCS) | Israeli Society of Hematology and Blood Transfusion | Karolinska Institute | Medical University of Lublin | Oncotyrol (Center for Personalized Cancer Medicine) | PETHEMA | Queen University of Belfast | Rigshospitalet | Royal Bournemouth | Spanish CETLAM Cooperative Group | The Fondazione Italiana Linfomi ONLUS | Università degli studi di Bari | Aldo Moro | Universitätsklinikum Essen | University Hospital Carl Gustav Carus Dresden | University of Eastern Piedmont and Oncology Institute of Oncology Institute of Southern Switzerland | University of Milano-Bicocca | University of Munich | University of Pisa | University of Southampton | Università Vita Salute San Raffaele.



Welcome to the 4th General Assembly 2019

With the first results in AML, CLL, and MM, our groups in MDS, ALL/Pediatrics, NHL working full steam ahead, and the increasing number of datasets in the HARMONY Big Data Platform, the 4th HARMONY General Assembly will be the perfect starting point for the second wave of HARMONY research projects.

Page | 3

Your participation as multidisciplinary experts in this new phase HARMONY is highly valued. We trust that through the various project updates, the research-a-thon sessions and the social program we can step up our mission to solve more key questions on hematologic cancers.

The 4th General Assembly is hosted by HARMONY Partner:



Content of this handout

1. Program Overview
2. Venue Floor Plan
3. Program in Detail
4. Instructions for the Research-a-Thon sessions
5. Participant Overview - overall
6. Communication, Dissemination Update
7. Notes

Practical information

Venue meetings 26 & 27 September 2019

[Palazzo Ximènes Panciatichi, Borgo Pinti, 68, 50121 Firenze](#)

Venue networking cocktails & dinner 26 September 2019

[Paszkowski caffè, Piazza della Repubblica 6, 50123 Firenze](#)

Contact persons

HARMONY Coordination Office: Santiago Moralejo - +34 616222324

HARMONY Communications: Ellen de Waal - +31 615102978



#Bigdataforbloodcancer:

Page | 4

HARMONY
can accelerate
your research
to benefit
patients with
Hematologic
Malignancies.

1. Program Overview

Program Overview

Thursday, 26th September 2019

Time	Program Feature	Room
09:30 – 10:00	Registration	
10:00 – 10:15	Opening Ceremony and Welcome	Main room Salone da Ballo
10:15 – 10:30	HARMONY achievements	Main room Salone da Ballo
10:30 – 12:00	Round Table	Main room Salone da Ballo
12:00 – 12:30	Update of HARMONY Results	Main room Salone da Ballo
12:30 – 12:50	Pitching Research section	Main room Salone da Ballo
12:50 – 13:00	Mid-Term Review procedure	Main room Salone da Ballo
13:00 – 14:00	Lunch including photo moment	Main room Salone da Ballo
14:00 – 19:00	Research-a-thons HMs	See programme
19:30	Networking cocktail + dinner	Caffe Paszkowski

Page | 6

Friday, 27th September 2019

Time	Program Feature	Room
08:30 – 09:30	Research-a-thons HMs	See program
09:30 – 10:30	Research-a-thon Cross-pillar	Main room Salone da Ballo
10:30 – 10:45	Coffee break	Main room Salone da Ballo
10:45 – 12:00	Presentation of Research Questions	Main room Salone da Ballo
12:00 – 12:30	Q&A session for data providers	Main room Salone da Ballo
12:30 – 13:00	Associated Members update session	Room C
13:00 – 13:15	Scientific and non-scientific dissemination	Main room Salone da Ballo
13:15 – 13:30	WRAP-UP and Closing of Working sessions	Main room Salone da Ballo
13:30 – 15:00	Networking lunch	
15:00	End of the 4th General Assembly	



Program Overview | continued

Out of program internal Alliance meetings

Page | 7

Wednesday, 25th September 2019

WP 6 Task meeting – upon invitation

14:00 – 15:45 Task 6.2 - "Sala A", Menarini offices, Via dei Sette Santi, 1 (Firenze)

16:00 – 17:00 Task 6.3 - "Sala A", Menarini offices, Via dei Sette Santi, 1 (Firenze)

Thursday, 26th September 2019

Internal Governing Bodies – upon invitation

08:00 – 09:50 F2F Steering Committee Meeting – Room B&D

18:00 – 19:00 F2F Executive Committee / Executive Advisory Panel Meeting – Room A

Friday, 27th September 2019

Internal Governing Bodies – upon invitation

12:30 – 13:30 F2F Ethics Advisory Board / WP8 Meeting – Room I

13:30 – 14:30 F2F Executive Committee / Ethics Advisory Board Debriefing – Room I



#Bigdataforbloodcancer:

Page | 8

Our Public and Private Alliance Partners, Patient Cluster and Associated Members are bringing together their best people, data, and knowledge to solve key questions on hematological cancers.

Challenges which can only be met by applying the most advanced Big Data technologies.

2.

Venue Floor Plan

Venue Floor Plan

Palazzo Ximenes Panciatichi

Page | 10



Venue Floor Plan | continued

Palazzo Ximenes Panciatichi | Ground Floor


Page | 11

Registration Area

Research-a-Thon Session rooms

ALL & Pediatrics: room I
CLL: room C
MDS: room B&D
MM: room E
NHL: room G

Entrance



Venue Floor Plan | continued

Palazzo Ximenes Panciatichi | First Floor



Main room
Salone da Ballo

Research-a-Thon Session room:
AML: room Salone da Ballo

3.

Program in Detail



Program in detail

Thursday, 26 September 2019

Page | 14

09:30 – 10:00 Registration and coffee/tea break

— Room: Salone de Ballo

10:00 – 10:15 **Opening Ceremony and Welcome**

Andrea Pellacani, General Manager, Menarini

10:15 – 10:30 **HARMONY achievements**

Jesús M. Hernández, IBSAL | HARMONY Project Coordinator

Frederico Calado, NOVARTIS | HARMONY Project Lead

10:30 – 12:00 **Round Table**

The value of data sharing, big data approaches, artificial intelligence and advances in data analysis, and HARMONY's unique position and added value for precision medicine.

Moderator

Bob Löwenberg, ErasmusMC | HARMONY *External Advisory Panel*

Participants

Kimmo Porkka, University of Helsinki, Member of European Hematology Association (EHA) Executive Board

Miklós Szócska, Semmelweis University

Christian Reich, IQVia

Nathan Intrator, Tel Aviv University



Program in detail | continued

Thursday, 26 September 2019

— Room: Salone de Ballo

Page | 15

12:00 – 12:30 **Update of HARMONY Results**

AML: A proof-of-concept study in AML: Big Data for Better AML Outcomes.
Impact of genomics and value of intensive treatment approaches in MDS/AML.

Lars Bullinger, Charité

MM: Revised International Staging System for Multiple Myeloma: extended follow-up in the European clinical trial population and evaluation of the efficacy of different novel agents and treatment approaches in subsets of patients with standard- and high-risk features

Mario Boccadoro, University of Turin

12:30 – 12:50 **Pitching Research section**

APL: Open issues in the management of Acute Promyelocytic Leukemia (APL)

Maria Teresa Voso, University of Rome Tor Vergata

MDS: Prognostic factors of treatment with hypomethylating agents in higher risk MDS and advanced Chronic Myelomonocytic Leukaemia (CMML)

Valeria Santini, FisMonlus Fondazione Italiana Sindromi Mielodisplastiche

NHL: Big Data for better outcomes of T-Cell Lymphomas – Bridging the gap between molecular understanding and treatment reality. Impact of Genomics on Prognostification and Treatment of T-Cell Lymphomas

Thomas Weber, Universitätsklinikum Halle (Saale)

CLL: Large-scale mutation analysis - Novel prognostic/predictive scheme for improved risk stratification aimed at personalized medicine

Lesley-Ann Sutton, ERIC European Research Initiative on CLL

12: 50 – 13:00 **Mid-Term Review procedure**

Karroum Oussama, Innovative Medicines Initiative, European Commission

13:00 – 14:00 **HARMONY Community Photo Moment**

Lunch



Program in detail | continued

Thursday, 26th September 2019

14:00 – 19:00 Research-a-thons

Page | 16

What is a research-a-thon? A research-a-thon is a collective marathon of multi-stakeholders that seek to either answer a research question or build a research resource. This method derives from the culture of hackathons, where IT developers get together for long hours to solve a software problem in a collaborative way. The word research-a-thon was coined by David K. Park, the Director of Special Projects at the Applied Statistics Center of Columbia University.

Main goal of the session: write a new research proposal, that is APPROVED at the General Assembly and ready for implementation.

You can find a briefing for the sessions **in** chapter 4.
Check the preliminary attendees per HM Research-a-thon in chapter 6.

Please not that a coffee/tea break is planned from 16:30-17:00.

HM	Room
ALL & Pediatrics	ROOM I
AML & APL	MAIN ROOM – Salone de Ballo
CLL	ROOM C
MDS	ROOM B&D
MM	ROOM E
NHL	ROOM G

19:30

Networking cocktail and dinner in

Paszkowski caffè
Piazza della Repubblica 6
50123 Firenze FI, Italia
Phone: +39 055 210236





Program in detail | continued

Friday, 27th September 2019

08:30 – 09:30 Research-a-thon continued

Page | 17

Review of work done the previous day and finalization of a research proposal per pillar.

HM	Room
ALL & Pediatrics	ROOM I
AML & APL	MAIN ROOM – Salone de Ballo
CLL	ROOM C
MDS	ROOM B&D
MM	ROOM E
NHL	ROOM G

— Room: Salone de Ballo

09:30 – 10:30 Research-a-thon – cross-pillar

Evaluation of surrogate outcomes and related regulatory strategies.

From a regulatory point of view, the operating characteristics of the regulatory rules that are based on surrogate endpoints are of high importance to understand the consequences of regulatory decisions based on surrogates and to potentially adjust regulatory rules. Join this working session to help us shaping the next HARMONY research project on regulatory strategies based on surrogate endpoints on AML.

10:30 – 10:45 Coffee/tea break

10:45 – 12:00 Presentation of Research Questions



Program in detail | continued

Friday, 27th September 2019

— Room: Salone de Ballo

Page | 18

12:00 – 12:30 **Q&A session for Public and Private Data Providers.**
Providing data to the HARMONY Data Platform. Focus on anonymization, security, what's my data going to be used for, data transfer process, and legal requirements.

Moderator

Jesús M. Hernández, IBSAL

Participants

Gabriele Nagel, Universitaet Ulm

Frederico Calado, NOVARTIS

Rubén Villoria, GMV

— Room C

12:30 – 13:00 **Associated Members update session – for Associated Members**

— Room: Salone de Ballo

12:30 – 13:00 **Making HARMONY “EMA compatible”: Qualification of novel methodologies (Task 6.4). – for Partners**

Pall Jonsson, NICE

Katy Harrison, NICE

Kyriaki Tzogani, EMA

13:00 – 13:15 **Communication and dissemination: Scientific and non-scientific
Current status and how to improve the project impact**

Ellen de Waal, European Hematology Association (EHA),
representing the HARMONY Communication team

13:15 – 13:30 **WRAP-UP and Closing of Working sessions**

Pam Bacon, CELGENE

Guillermo Sanz, HULAFE

13:30 – 15:00 **NETWORKING LUNCH and end of the 4th General Assembly**



4. Briefing Research-a-Thon



Briefing Research-a-Thon sessions

Introduction

A research-a-thon is a collective marathon of multi-stakeholders that seek to either answer a research question or build a research resource. This method derives from the culture of hackathons, where IT developers get together for long hours to solve a software problem in a collaborative way. The word research-a-thon was coined by David K. Park, the Director of Special Projects at the Applied Statistics Center of Columbia University.

Page | 20

Objective

Write new research proposals, APPROVED at the General Assembly and ready for implementation.

Work process HARMONY Research-a-thons

Including Instructions for the completion of the Research-a-thon working posters

1

The Challenge

Define the unmet need – sessions teams will rank the research questions from a gross list of questions prioritized by the HM KOLs.

Working poster: This first section automatically includes the themes already published on the website and that will be used to start the discussion. Please see example for AML.

In addition, this section should include the rationality of the unmet need.

- *Why is this question important?*
- *Does it need to be refined?*
- *Does it comply with HARMONY standards? Unique, feasible, with scientific impact*

2

Scientific Questions and Impact

Determine what objective(s) and/or hypothesis will be evaluated; Determine the outcomes, risk factors, surrogate parameters, end-points and measures; Define the sample size required to answer the question.

Working poster: This section should include the different questions that should be addressed for each unmet need, plus the expected impact.

Briefing Research-a-Thon sessions | continued

3 Required data fields and analytical approach

Page | 21

Define the key variables that need to be present in the data; Define the analytical and statistical methods to be applied; Define data sources/providers that could be included in the HARMONY Big Data Platform to solve the question.

Working poster:

- *Required data fields: Key variables which need to be present in the data*
- *Analytical approach: Minimum required; Existing algorithms; Tools; Modelling and Methods*

4 Project partnership

Identify teams for the selected projects.

Working poster:

- *Suggested data sources for the research project: CWGs, Hospitals, Clinical trials...*
- *Number of datasets available*
- *Analytics team*
- *Contact list for the project (including emails)*

5 Ethics questions

How is this proposal intending to address any anticipated ethical concerns or difficulties in relation to the aims and objectives, the research and analysis methodology, and the potential of the Research Project?

6 Next steps and expected time frame

Determine a credible calendar with action list for implementation.

Working poster: This section should point out the expected timeframe for the research project, what steps will be taken, and who is in charge of such actions to ensure the timely delivery of results.



Briefing Research-a-Thon sessions | continued

Topics and key questions to address in the HM specific Research-a-thons

Page | 22

ALL

- KMT2A (MM) re-arrangements in ALL patients;
- Adult B cell precursors in ALL.

AML

- The cooperating mutational pattern of cases showing mutations in classical splicing factors such as SRSF2, SF3B1 etc., and investigate in further depths the cohesion factor mutations which are also involved in transcriptional regulation and splicing;
- Differences in mutational patterns with regard to gender differences and performing gender-dependent outcome analyses in defined AML subgroups;
- Mutational profiles of sAML and tAML cases as well as into de novo AML that was primary refractory or showed early relapse.
- European Public-Private Data Collection Leads the Way: First Results of the Proof-of-Principle Study in Acute Myeloid Leukemia.

CLL

- Secondary neoplasia in the history of CLL (with or without therapies; CIT or novel therapies);
- Correlation between MRD and outcomes in CLL;
- Validation of establishing UMRD as a relevant primary endpoint in CLL.

MDS

- Event free survival (EFS) as surrogate endpoint for OS to be used in clinical trials. Implement recently modified IWG criteria for response;
- Are patients with isolated monosomy 7 more sensitive to HMAs? (and the effect of cytogenetic alterations on response);
- Specific outcome of patients with TP 53 mutation after HMAs. And other mutations and commutations?
- Outcome of CMML dysplastic (azacytidine) and proliferative (decitabine in clinical trials).
- Incidence and prognostic value of febrile neutropenia and relative treatment/ prophylaxis.
- Characterize features of specific subgroups of patients: long responders, elderly, hypocellular marrow etc.;
- Evaluation of clonal evolution during/after HMA therapy (for cases with sequential samples);
- HMAs as bridge to transplant: how many cycles? Which kind of response?



Briefing Research-a-Thon sessions | continued

MM

- Predictors of initial response duration in patients newly diagnosed with MM;
- Are there specific predictors of patients who relapse early after initial treatment?

Page | 23

NHL

DLBCL:

- Newly approved novel targeted agents bring both value and complication to treatment selection and sequencing in DLBCL.
- Is there space to improve R-CHOP strategy by adding new drugs, drug combinations or sequences? Some recent attempts have failed, why? Will large scale genetic datasets help to refine first-line treatment strategies?
- Novel therapeutics in R/R DLBCL are needed, we still deal with poor survival outcomes despite salvage chemotherapy with or without SCT in a relevant number of patients.
- High-grade B-cell lymphoma /Double-hit lymphoma (DHL) need new therapeutic approaches: anti BCL2, MYC, or other associated pathways.
- There is limited data on differential therapy by DLBCL subtype.
- DLBCL remains a heterogeneous disease. We need refinements in the understanding of the complex pathogenesis and to improve strategies for treatment choice.

PTCL:

- Is it pcALCL or psALCL? ALCL with uncertain classification regarding primary systemic vs. primary cutaneous ALCL origin. Genetic and biological characterization and impact of treatment approach on outcome.
- What patients benefits from upfront SCT; clinical, biological and genetic stratification.



#Bigdataforbloodcancer:

Page | 24

The HARMONY Alliance
stands for open science
because it can speed up
progress in medical
sciences.

5.

Participant Overview

<u>First name</u>	<u>Suffix</u>	<u>Last name</u>	<u>Organization</u>	<u>HM Research-a-Thon</u>	<u>HARMONY Role</u>
Cristina		Abad Rodríguez	HULAFE	NHL	Partner
María		Abaigar	Charité University Medicine Berlin	AML & APL	Partner
Pietro	D'	Addabbo	Universita' di Bari	AML & APL	AM
Ana		Alfonso Piérولا	Universidad de Navarra	MDS	Partner
Mattia		Algeri	Ospedale Pediatrico Bambino Gesù, Rome Italy	Pediatric HMs	Partner
Farzad		Ali	Pfizer	ALL	Other
Chiara		Azzurrini	Menarini Ricerche S.p.A.	Tbd	Partner
Pam		Bacon	Celgene	AML & APL	Partner
Simone		Baldini	Menarini Ricerche SpA	AML & APL	Partner
Enrico		Balleari	FISM Onlus	MDS	Partner
Nicola		Barbarini	FISM Onlus	MDS	Partner
Martje		Barbus	AbbVie	MM	Partner
Lauren		Becnel	Pfizer	ALL	Other
Norbert		Benda	BfArM	AML & APL	Partner
Tamás		Bereczky	LeukaNET	Pediatric HMs	Partner
Ettore		Biagi	Celgene Corporation	ALL	Partner
Catalin		Bobirca	Novartis	MDS	Partner
Mario		Boccadoro	University of Turin	MM	Partner
Natacha		Bolanos	Lymphoma Coalition	NHL	Patient Cluster
Francisco		Bosch Albareda	University Hospital Vall d'Hebron	CLL	Partner
Andreas		Bruederle	Novartis Oncology	MDS	Partner

<u>First name</u>	<u>Suffix</u>	<u>Last name</u>	<u>Organization</u>	<u>HM Research-a-Thon</u>	<u>HARMONY Role</u>
Lars		Bullinger	Charité University Medicine Berlin	AML & APL	Partner
John		Butler-Ransohoff	Bayer AG	NHL	Partner
Frederico		Calado	Novartis	MDS	Partner
Angela		Capriati	Menarini Ricerche S.p.A.	Tbd	Partner
Gastone		Castellani	University of Bologna	ALL	Partner
Francesco		Cerisoli	European Hematology Association	MM	Partner
Helene		Chevrou-Severac	Celgene International	MM	Partner
Andrea		Chierici	INFN-CNAF	ALL	Partner
Daniela		Cilloni	University of Turin	MDS	Partner
Marino		Clavio	FISM Onlus	MDS	Partner
Carlos		Collados Clares	AEMPS	MM	Partner
Minxian		Conge	AbbVie	AML & APL	Partner
Jan		Cools	VIB -KU Leuven	ALL	Partner
Annamaria		Coscarella	Menarini Ricerche S.p.A.	Tbd	Partner
Bruno		Costa	Celgene International	MM	Partner
Elena		Crisà	UNIPO, Hematology Division / FISM	MDS	AM
Anne		Cromer	LYSARC	NHL	Partner
Mehul		Dalal	Takeda Pharmaceuticals	MDS	Partner
Inez		de Beaufort	Erasmus University Rotterdam	ALL	Partner
Hartmut		Döhner	University of Ulm	AML & APL	Partner
Henrik		Edgren	MediSapiens	AML & APL	Partner
Blanca		Espinet	Hospital del Mar, Barcelona	CLL	AM

<u>First name</u>	<u>Suffix</u>	<u>Last name</u>	<u>Organization</u>	<u>HM Research-a-Thon</u>	<u>HARMONY Role</u>
Neus		Fabregat-Cabello	HULAFE	MDS	Partner
Piero		Fantacci	Menarini Ricerche SpA	AML & APL	Partner
Carla		Faralli	University of Bologna	Tbd	Partner
Bruno		Fattizzo	Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico	MDS	AM
Pierre		Fenaux	Groupe Francophone des Myelodysplasies	MDS	Partner
Roxanne		Ferdinand	Pfizer	AML & APL	Other
Sara		Galimberti	University of Pisa	NHL	AM
Lauris		Gastaud	ALFA	Tbd	AM
Jan		Geissler	LeukaNET	AML & APL	Partner
Paolo		Ghia	European Research Initiative on CLL - ERIC	CLL	Partner
Yann		Guillevic	Celgene	Pediatric HMs	Partner
Sibel		Güneş	Novartis	AML & APL	Partner
Katy		Harrison	NICE	MDS	Partner
Ahmet		Hasaligil	Astellas	AML & APL	Other
Caroline		Heckman	University of Helsinki	AML & APL	Partner
Rüdiger		Hehlmann	ELN	AML	Partner
Ana		Heredia Casanoves	GMV Soluciones Globales Internet	NHL	Partner
Ana		Hernández Blázquez	IBSAL	ALL	Partner
Jesús María		Hernández Rivas	IBSAL	AML & APL	Partner
Brian		Huntly	University of Cambridge	AML & APL	Partner
Jessica		Hutti	AbbVie	MDS	Partner
Nathan		Intrator	Neurosteer LTD	Pediatric HMs	Other

<u>First name</u>	<u>Suffix</u>	<u>Last name</u>	<u>Organization</u>	<u>HM Research-a-Thon</u>	<u>HARMONY Role</u>
Sofia		Iqbal	Johnson & Johnson	ALL	Partner
Laura		Jamilis	GMV Soluciones Globales Internet	AML & APL	Partner
Philip		Johnson	Pfizer	AML & APL	Other
Pall		Jonsson	NICE	ALL	Partner
Anna		Kabanova	European Hematology Association (Young EHA Committee)	CLL	Partner
Oussama		Karroum	Innovative Medicine Initiative	Pediatric HMs	Funder
Sudeep		Karve	AbbVie	MM	Partner
Charikleia		Kelaidi	Agia Sofia Children's Hospital	Pediatric HMs	AM
Anita		Kienesberger	Öst. Kinder-Krebs-Hilfe	Pediatric HMs	Patient Cluster
Jana		Kotaskova	Masaryk University	CLL	Partner
Romika		Kumari	Institute for Molecular Medicine Finland	MM	Partner
Maria		Laaksonen	MediSapiens	AML & APL	Partner
Katharina		Lang	Charité University Medicine Berlin	NHL	Partner
Soren		Lehmann	Karolinska Institute	AML & APL	AM
Stephane		Lejeune	EORTC	ALL	Partner
Alan		List	Moffitt Cancer Center and Research Institute	MDS	EAP
Franco		Locatelli	Ospedale Pediatrico Bambino Gesù, Rome Italy	Pediatric HMs	Partner
Bob		Löwenberg	Erasmus University Medical Center	AML & APL	Partner
Rafal		Machowicz	Medical University of Warsaw	MDS	AM
Paolo		Mariotti	Inst. Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS	AML & APL	AM
Thomas		Marshall	AbbVie	CLL	Partner

<u>First name</u>	<u>Suffix</u>	<u>Last name</u>	<u>Organization</u>	<u>HM Research-a-Thon</u>	<u>HARMONY Role</u>
Barbara		Martelli	INFN - CNAF	AML & APL	Partner
Javier		Martínez Elicegui	IBSAL	AML & APL	Partner
Ilaria		Massa	Inst. Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS	NHL	AM
Tommaso		Matteuzzi	University of Bologna	Tbd	Partner
Emanuela		Messa	FISM Onlus	MDS	Partner
Klaus		Metzeler	AML-CG München	AML & APL	AM
Ken		Mills	Queen's University Belfast	AML & APL	AM
Elvira		Mora Casterá	HULAFE	MDS	Partner
Santiago		Moralejo	IBSAL	MM	Partner
Kate		Morgan	Myeloma Patients Europe	MM	Patient Cluster
Sandra		Mossuto	FISM Onlus	MDS	Partner
Vasile		Musteata	State University of Medicine and Pharmacy "N. Testemitanu", Institute of Oncology	AML & APL	AM
Gabriele		Nagel	University of Ulm	AML & APL	Partner
Letizia		Nidiaci	Menarini Ricerche SpA	AML & APL	Partner
Enkeleida		Nikai	Johnson & Johnson	ALL	Partner
Pasquale		Nicola	FISM Onlus	MDS	Partner
Diana		O'Rourke	NICE	ALL	Partner
David		Oscier	Royal Bournemouth Hospital	CLL	AM
Gert		Ossenkoppele	Amsterdam UMC / VUMC	AML & APL	Partner
Francesca		Paoloni	Fondazione GIMEMA	ALL	AM
Anna Maria		Pelizzari	FISM Onlus	MDS	Partner

<u>First name</u>	<u>Suffix</u>	<u>Last name</u>	<u>Organization</u>	<u>HM Research-a-Thon</u>	<u>HARMONY Role</u>
Andrea		Pellacani	Menarini Ricerche S.p.A.	Tbd	Partner
Andrea		Pellagatti	University of Oxford	MDS	AM
Zack		Pemberton- Whiteley	Acute Leukemia Advocates Network	AML & APL	Patient Cluster
Bauer		Peter	Medical University of Vienna	Pediatric HMs	EAB
Giulia		Petri	Menarini Ricerche S.p.A.	Tbd	Partner
Robert		Plovnick	American Society of Hematology	MM	Other
Antonella		Poloni	FISM Onlus	MDS	Partner
Elisabetta		Poluzzi	University of Bologna	Tbd	Partner
Kimmo		Porkka	Helsinki University Hospital Comprehensive Cancer Center	AML & APL	Partner
Carla		Portulano	Menarini Ricerche SpA	AML & APL	Partner
Sarka		Pospisilova	Masaryk University	CLL	Partner
Emilie		Prazakova	Takeda	MDS	Partner
Christian		Reich	IQVIA	MM	Other
Elena	del	Rey	SYNAPSE	Pediatric HMs	Partner
Jordi		Ribera	Josep Carreras Leukaemia Research Institute	ALL	Partner
Ana Eugenia		Rodríguez Vicente	IBSAL/CIC	ALL	Partner
Viviana		Roman	Carol Dávila	CLL	AM
Priscilla	de	Rosa	Menarini Ricerche	AML & APL	Partner
Maria		Roumelioti	National and Kapodistrian University of Athens	AML & APL	AM
Kavita		Sail	AbbVie	CLL	Partner
Valeria		Santini	FISM Onlus	MDS	Partner
Guillermo		Sanz Santillana	HULAFE	MDS	Partner

<u>First name</u>	<u>Suffix</u>	<u>Last name</u>	<u>Organization</u>	<u>HM Research-a-Thon</u>	<u>HARMONY Role</u>
Simona		Scartoni	Menarini Ricerche SpA	AML & APL	Partner
Renate		Schulze-Rath	Bayer AG	NHL	Partner
Carin		Smand	European Hematology Association	Tbd	Partner
Marta		Sobas	Medical University of Wroclaw, Poland	AML & APL	AM
Stefano		Soddu	Fondazione GIMEMA	ALL	AM
Alexandros		Spyridonidis	EBMT	AML & APL	Partner
Eric		Sträng	Charité University Medicine Berlin	AML & APL	Partner
Jonathan		Strefford	University of Southampton	CLL	AM
Vladimir		Strugov	Almazov National Medical Research centre	CLL	AM
Anna		Sureda	EBMT	NHL	Partner
Lesley-Ann		Sutton	European Research Initiative on CLL - ERIC	CLL	Partner
Miklos		Szocska	Semmelweis University	Tbd	Other
Francesco	di	Tano	University of Bologna	Tbd	Partner
Ghislaine	van	Thiel	UMC Utrecht	AML & APL	Other
Antoine		Tinel	Celgene International	MM	Partner
Giulia		Tonini	Menarini Ricerche SpA	AML & APL	Partner
Mirjami		Tran Minh	MDS Alliance	MDS	Patient Cluster
Amin		Turki	Universitätsklinikum Essen	ALL	AM
Sean		Turner	AbbVie	CLL	Partner
Kyriaki		Tzogani	EMA	AML & APL	Other
Michel		Van Speybroeck	Janssen	Pediatric HMs	Partner
Alberto		Vasconcelos	Celgene	MDS	Partner

<u>First name</u>	<u>Suffix</u>	<u>Last name</u>	<u>Organization</u>	<u>HM Research-a-Thon</u>	<u>HARMONY Role</u>
María Belén		Vidriales	Complejo Asistencial Universitario de Salamanca	AML & APL	Partner
Marco		Vignetti	Fondazione GIMEMA	AML & APL	AM
Rubén		Villoria Medina	GMV Soluciones Globales Internet	CLL	Partner
Maria Cristina		Vistoli	INFN - CNAF	AML & APL	Partner
Maria Teresa		Voso	Tor Vergata University-Rome	AML & APL	Partner
Mirko		Vukcevic	Novartis	AML & APL	Partner
Ellen	de	Waal	European Hematology Association	AML & APL	Partner
Thomas		Weber	University Hospital Halle (Saale)	NHL	AM
Sally		Wetten	Amgen	MM	Partner
Jamie		Wilkinson	Amgen	MM	Partner
Dorothee		Wirtz	BfArM	AML & APL	Partner
William		Wood	University of North Carolina	MM	Other
Anja		Wrisch	AbbVie	AML & APL	Partner
Gabriela		Yumi Gómez	AEMPS	AML & APL	Partner



#Bigdataforbloodcancer:

Page | 34

Sharing anonymized data in a secure and transparent way, for research purposes, is like a new form of blood donation in the era of digitalization and Big Data. In result, it also has the power to save human lives.



6.

Communication Dissemination Update

Publications

View all publications at the HARMONY Community Forum, <https://internal.harmony-alliance.eu/>, or at the HARMONY web page Results, www.harmony-alliance.eu/results.

Page | 36



Big Data for Better Outcome of T-Cell Lymphomas: Impact of Genomics on Prognostification, Treatment and Classification of T-Cell Lymphomas

N. Bolanos, M. Dreyling, G. Salles, S. Montoto, T. Weber



Optimizing prognostication and personalizing treatment in Multiple Myeloma

MM pilot project within the HARMONY Alliance



Identification of prognostic factors for hypomethylating agent therapy and intensive chemotherapy in higher risk Myelodysplastic Syndromes

Valeria Santini¹, Pierre Fenaux², Andrea Kündgen³, Alberto Vasconcelos⁴

Affiliations: ¹Fondazione Italiana Sindromi, Italy; ²Groupe Francophone des Myélodysplasies (GFM), France; ³Heinrich-Heine Universität-Düsseldorf/Hospital, Germany; ⁴Celgene, Switzerland



Open issues in the management of Acute Promyelocytic Leukemia

Maria Teresa Voso¹, Marco Vignetti², Miguel Sanz³, Pau Montesinos⁴

Dedicated to Francesco Lo Coco¹


Affiliations: ¹Tor Vergata University, Rome, Italy; ²Fondazione GIMEMA, Rome, Italy; ³Hospital Universitario, Pineda de Mar, Valencia, Spain



Establishing a European knowledge bank for evaluating risk factors in Acute Lymphoblastic Leukaemia

Professor Anthony Moorman (PI), Anna Halstead (Project Manager)

Newcastle University



European Public-Private Data Collection Leads the Way: First Results of the Proof-of-Principle Study in Acute Myeloid Leukemia

Lars Bullinger¹, Peter Valk², Jurjen Verdonk³, Elisee Mouton⁴, René Assel⁵, Joseph Martinez Lopez⁶, Hervé Dombret⁷, Pau Montesinos⁸, Jorge Sierra⁹, Claude Preudhomme¹⁰, Frederik Damm¹¹, Ron Mink¹², Jai Mayur¹³, Christian Thiede¹⁴, Maria Teresa Voso¹⁵, Sergio Amadori¹⁶, Guillermo Sanz¹⁷, Mirko Vukosavljevic¹⁸, Pamela Bassett¹⁹, Robin Williams Medford²⁰, Michael Van Spanhelde²¹, Rory Sandhu²², Renato Schulze-Rath²³, Ismael Maria Hernández²⁴, Francesco Lo-Coco²⁵, Brian Huntley²⁶, Harmut Döhmer²⁷, Gert Ossenkoppele²⁸



Prognostic factors and outcome of Multiple Myeloma patients enrolled in European clinical trials after a long-term follow-up

Mattia D'Agostino¹, Alessandra Larocca², Jesus San Miguel³, Pieter Sonneveld⁴, Maria Victoria Mateos⁵, Philippe Moreau⁶, Michele Cairo⁷, Mario Boccadoro⁸


Affiliations: ¹University of Perugia, Italy; ²University of Bari, Italy; ³University of Valencia, Spain; ⁴University of Groningen, The Netherlands; ⁵University of Salamanca, Spain; ⁶University of Bordeaux, France; ⁷University of Milan, Italy; ⁸University of Rome, Italy



HARMONY Platform Using Big Data to fight Blood Cancers

Maria Abizán¹, Renata Schulze-Rath², Ana Eugenia Rodríguez-Vicente³, Santiago Moraleda del-Arcer⁴, ABT Taylor⁵, Lars Bullinger⁶

Affiliations: ¹Group of Molecular Genetics/Oncogenetics - Institute of Biomedical Research of Salamanca (IBSA); ²Cancer Research Center - University of Salamanca (USAL); ³CSCG, Spain; ⁴Spain; ⁵Germany; ⁶Institute of Biomedical Research of Salamanca (IBSA); ⁷Spain; ⁸United Kingdom; ⁹Canada; ¹⁰University of Bonn, Germany



15 years of Hematological Malignancies outcome reporting to NICE: Data for core outcome sets

Katy Harrison, Stephen Robinson, Pall Jonsson

National Institute for Health and Care Excellence (NICE)



HARMONY White Paper: Big Data to enable better and faster treatment for Patients with Blood Cancer.

Horgan, D., Smand, C., de Waal, E.

Page | 37



**HARMONY
Anonymization
Concept Reconciles
Data Quality, Safety,
and Privacy**
WP7



**HARMONY: Next-
generation
science: Sharing
data and
knowledge**
WP7




**Algorithms to transform
knowledge into better
medicine outcomes. The
HARMONY BigData
Platform: What is it and
how does it work?**
WP7



Network integration of multi-tumour omics data suggests novel targeting strategies

do Valle, Í. F., Menichetti, G., Simonetti, G., Bruno, S., Zironi, I., Durso, D. F., ... Remondini, D.



Statistical modelling of CG interdistance across multiple organisms

Merlotti A., Faria do Valle I., Castellani G. and Remondini D.



Big data for better outcomes: supporting health care system transformation in Europe

Szócska, M., Jayawardana, S., Smand, C., Salimullah, T., Reed, C., Hanif, S.

Presentations at international and/or scientific meetings

Thank you, all HARMONY Ambassadors, for sharing our vision, representing our community and sharing our messages at inspiring meetings. **An impression:**
View at www.harmony-alliance.eu/en/meet-us

Page | 38




International Workshop on CLL
20-23 SEPTEMBER 2019 EDINBURGH

Other event

HARMONY present at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

Edinburgh, Great Britain
September 20, 2019 - September 23, 2019



26 & 27 September 2019
Florence, Italy

HARMONY event

HARMONY Alliance: 4th General Assembly for Partners and Associated Members

Florence, Italy
September 26, 2019 - September 27, 2019



27 SEPT – 1 OCT 2019
Barcelona, Spain

Other event

HARMONY Partners present at ESMO 2019 congress

Barcelona, Spain
September 27, 2019 - October 01, 2019



12th Edition - Autumn
MEDAFFAIRS
Leaders Forum Europe
Hilton Zurich Airport, Zurich, Switzerland
November 5-7, 2019

Other event

HARMONY presenting at the 12th edition Medaffairs Leaders Forum Europe

Zurich, Switzerland
November 05, 2019 - November 07, 2019




2-3 December 2019, Berlin

Other event

HARMONY presenting at the Inaugural Cancer Precision Medicine Forum 2019

Berlin, Germany
December 02, 2019 - December 03, 2019



Other event

HARMONY Alliance participates in BioDataWorld 2019 with IMI Big Data Projects: EHDEN, PIONEER, BigData@Heart.

December 04, 2019 - December 05, 2019



ASH 2019
AMERICAN SOCIETY OF HEMATOLOGY
61ST ANNUAL MEETING
07 Dec - 10 Dec, 2019
Orlando, Florida, USA

Other event

HARMONY Alliance participates in ASH2019: 61th Annual Meeting of the American Society of Hematology

Orlando, USA
December 07, 2019 - December 10, 2019



Other event

HARMONY represented at the 17th International Myeloma Workshop

Boston, USA
September 12, 2019 - September 15, 2019



Other event

HARMONY represented at ECCO2019: European Cancer Summit

Brussels, Belgium
September 12, 2019 - September 14, 2019



Partner event

Let's meet in Amsterdam at the 24th Annual Congress of the European Hematology Association.

Amsterdam, The Netherlands
June 13, 2019 - June 16, 2019



Other event

Let's connect at ASCO2019 organized by the American Society of Clinical Oncology

Chicago, USA
May 31, 2019 - June 01, 2019



Other event

HARMONY best practice presentation at IMI project communication event

Brussels, Belgium
April 02, 2019



Partner event

HARMONY participates in 16th European LeukemiaNet Symposium

Mannheim, Germany
February 12, 2019



Other event

HARMONY is presenting at the IMI 10th Anniversary Scientific Symposium

Brussels, Belgium
October 22, 2018 - October 23, 2018



Other event

HARMONY participating in BD4BO "In Data we trust" Symposium


Brussels, Belgium
October 11, 2018



Other event

HARMONY exhibiting at ÖPPM "Joining Forces for Personalized Medicine 2nd Annual Meeting"

Graz, Austria
October 11, 2018 - October 12, 2018



HARMONY event

HARMONY Alliance: 3rd General Assembly for Partners and Associated Members

Valencia, Spain
October 04, 2018 - October 05, 2018



Other event

HARMONY participates in IPAP'18: 1st World Congress of Faculties of Pharmacy

September 24, 2018 - September 28, 2018



WEBINAR INVITATION

"Leapfrogging Legacy Processes for Data Driven Decision Making"

17 September 2018, 15.00-16.00 CET

Other event

BD4BO webinar "Leapfrogging Legacy Processes for Data Driven Decision Making"

September 17, 2018




EUROPEAN
HEMATOLOGY
ASSOCIATION

HARMONY event

EHA-HARMONY WP2 KOL Meeting

The Hague, The Netherlands
February 05, 2019



HARMONY event

Masterclass HARMONY Patient Cluster

The Hague, The Netherlands
February 04, 2019



INVITATION
14.12.2018
INNOVATIVE MEDICINES INITIATIVE
NETWORKING IN LUXEMBOURG

Other event

HARMONY presents at IMI Networking event Luxembourg

Dudelange, Luxembourg
December 14, 2018



60th American Society of Hematology (ASH) 2018

Other event

HARMONY Alliance at ASH2018: 60th Annual Meeting of the American Society of Hematology

San Diego, USA
December 01, 2018 - December 04, 2018



2018
EAPM
MILAN

2nd European Alliance for Personalised Medicine Congress Forward as One: Integrating Innovation into Europe's Healthcare Systems 26 - 28 November 2018 - Milan Italy

Partner event

2nd EAPM Annual Congress organized by HARMONY Partner: European Alliance for Personalised Medicine

Milan, Italy
November 26, 2018 - November 28, 2018



BD4BO

Other event

HARMONY present at the BD4BO General Assembly

Brussels, Belgium
November 20, 2018




ECCO2018
EUROPEAN CANCER SUMMIT

Other event

HARMONY presenting at ECCO2018

September 07, 2018 - September 08, 2018



BIG DATA IN HEALTH - IMI'S HARMONY PROJECT

Other event

HARMONY presenting at IMI breakfast debate hosted by MEP Soledad Cabezon Ruiz, about BigData & Health

June 19, 2018 - June 20, 2018




STOCKHOLM 23RD CONGRESS
JUNE 14 - 17 | 2018
European Hematology Association

Partner event

See you in Stockholm? Let's connect at the 23rd Annual Congress of the European Hematology Association (EHA23).

Stockholm, Sweden
June 13, 2018 - June 17, 2018



Other event

HARMONY Partner presenting at BD4BO/DO-IT webinar on outcomes standardization.

May 15, 2018



17th Annual Bio-IT World CONFERENCE & EXPO '18
Building a global network for precision medicine by uniting the Bio-IT community

Other event

HARMONY present at Bio-IT World Conference & Expo 2018

Boston, USA
May 15, 2018 - May 17, 2018



1st European Myeloma Network Meeting

Partner event

Meet HARMONY at the First European Myeloma Network Meeting

Turin, Italy
April 19, 2018 - April 21, 2018

General Assemblies

- **Save the date: 5th General Assembly:**
14 and 15 October, The Netherlands
- **4th General Assembly:**
26 and 27 September 2019, Florence, Italy
- **3rd General Assembly:** 4 and 5 October 2018, Valencia, Spain
- **2nd General Assembly:** 23 and 24 October 2017, Berlin, Germany
- **1st General Assembly:**
16 and 17 January 2017, Salamanca, Spain






Videos

Thank you, all HARMONY Ambassadors, for taking the time to develop a vast amount of personal video messages we were able to share through our online channels. **An impression:**


Page | 42



Online engagement

Thank you, all HARMONY Ambassadors, for sharing and posting about the HARMONY work and efforts. **An impression of our outreach – summarized:**

Page | 43



www.harmony-alliance.eu

<https://internal.harmony-alliance.eu/>

@HARMONYNetEU

www.linkedin.com/company/harmony-alliance/

Need content or support to develop HARMONY messages targeted at your communication channels? Don't hesitate and contact the HARMONY Communication Office:

- Ellen de Waal – e.dewaal@ehaweb.org

#Bigdataforbloodcancer:


The HARMONY Big Data Platform captures 45,000 data records from European blood cancer patients by 2019 and will expand to 100,00 sets by 2021.


Includes diagnostics, genomics, treatment choices, and outcomes.

Focus on ALL, AML, CLL, MDS, MM, NHL and Pediatric HM.

7.

Notes





Contact

HARMONY Coordination Office

Institute of BioMedical Research of Salamanca
(IBSAL), Salamanca, Spain
+34 678 841 121
harmonyoffice@ibsal.es

HARMONY Communications Office

European Hematology Associations (EHA),
The Hague, The Netherlands
+31 70 302 0099
communications@harmony-alliance.eu

www.harmony-alliance.eu
[@harmonyNetEU](#)



About the HARMONY Alliance: Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Hematology

The HARMONY Alliance is a European Network of Excellence for Big Data in Hematology, consisting of 53 partners and 24 Associated Members. Our goal is unlocking valuable knowledge on hematologic malignancies (HMs). The HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.

HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

